Cover Image

Dual biological role and clinical impact of de novo chromatin activation in chronic lymphocytic leukemia

Previous studies have reported that chronic lymphocytic leukemia (CLL) shows a de novo chromatin activation pattern compared with normal B cells. Here, we explored whether the level of chromatin activation is related to the clinical behavior of CLL. We identified that, in some regulatory regions, in...

Full description

Saved in:
Bibliographic Details
Main Authors: Chapaprieta, Vicente (Author) , Maiques-Diaz, Alba (Author) , Nadeu, Ferran (Author) , Clot, Guillem (Author) , Massoni-Badosa, Ramon (Author) , Mozas, Pablo (Author) , Mateos-Jaimez, Judith (Author) , Vidal, Anna (Author) , Charalampopoulou, Stella (Author) , Duran-Ferrer, Martí (Author) , Royo, Romina (Author) , Russiñol, Núria (Author) , Llaó-Cid, Laura (Author) , Piñeyroa, Juan A. (Author) , Villamor, Neus (Author) , Heyn, Holger (Author) , Herbst, Sophie A. (Author) , Lu, Junyan (Author) , Bryant, Dean J. (Author) , Strefford, Jonathan C. (Author) , Dietrich, Sascha (Author) , Zenz, Thorsten (Author) , Delgado, Julio (Author) , López-Guillermo, Armando (Author) , Campo, Elias (Author) , Martin-Subero, Jose I. (Author)
Format: Article (Journal)
Language:English
Published: May 22 2025
In: Blood
Year: 2025, Volume: 145, Issue: 21, Pages: 2473-2487
ISSN:1528-0020
DOI:10.1182/blood.2024025396
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1182/blood.2024025396
Get full text
Author Notes:Vicente Chapaprieta, Alba Maiques-Diaz, Ferran Nadeu, Guillem Clot, Ramon Massoni-Badosa, Pablo Mozas, Judith Mateos-Jaimez, Anna Vidal, Stella Charalampopoulou, Martí Duran-Ferrer, Romina Royo, Núria Russiñol, Laura Llaó-Cid, Juan A. Piñeyroa, Neus Villamor, Holger Heyn, Sophie A. Herbst, Junyan Lu, Dean J. Bryant, Jonathan C. Strefford, Sascha Dietrich, Thorsten Zenz, Julio Delgado, Armando López-Guillermo, Elias Campo, Jose I. Martin-Subero
Description
Summary:Previous studies have reported that chronic lymphocytic leukemia (CLL) shows a de novo chromatin activation pattern compared with normal B cells. Here, we explored whether the level of chromatin activation is related to the clinical behavior of CLL. We identified that, in some regulatory regions, increased de novo chromatin activation is linked to clinical progression, whereas, in other regions, it is associated with an indolent course. We next developed 2 prognostic scores for progressive and indolent disease, respectively, calculated a single score representing the balance between them, and further generated surrogate scores based on gene and protein expression of the target genes. The balance score outperformed the clinical impact of the 2 individual scores, because it seemed to capture the prognostic information provided by each of them. Biologically, CLLs with higher balance score showed increased activation of tumor necrosis factor alpha (TNF-α)/NF-κB and mTOR signaling pathways. Regulatory programs related to progression were predominantly activated in the lymph node microenvironment, whereas those linked to indolent disease appeared to be microenvironment independent. Finally, we thoroughly validated the balance score as a powerful and independent quantitative prognostic factor for time to first treatment across independent CLL cohorts and data modalities, such as chromatin, transcriptome, or proteome data. Our findings support the concept that de novo acquisition of chromatin changes in CLL cells plays a dual biological role, and the balance between proprogression and proindolence is a strong independent determinant of CLL prognosis.
Item Description:Zuerst veröffentlicht: 22. Januar 2025
Gesehen am 24.09.2025
Physical Description:Online Resource
ISSN:1528-0020
DOI:10.1182/blood.2024025396

Similar Items